Sustained Anti-Thrombogenic Surface Treatment for Indwelling Medical Devices

Apr 25, 2001, 01:00 ET from STS Biopolymers, Inc.

    HENRIETTA, N.Y., April 25 /PRNewswire/ -- STS Biopolymers has developed
 heparin-containing polymer coatings (MEDI-COAT(TM)) for use on implants and
 indwelling devices, such as catheters and stents, to render them
 hemocompatible for sustained periods.  A research grant from the National
 Institutes of Health will allow STS Biopolymers to further develop and
 investigate "long-term" anti-thrombogenic surface coatings.
     When blood comes in contact with foreign surfaces there is an activation
 of the body's coagulation and inflammation systems, known as thrombosis.  The
 clinical means to prevent thrombosis is to administer systemic anticoagulants,
 such as heparin and warfarin.
     The STS Biopolymers' patented MEDI-COAT(TM) system consists of an inert,
 biocompatible polymer matrix used to entrap heparin complexes on the surface
 of medical devices.  The polymer coating acts as a reservoir for the heparin
 complex, releasing the agent slowly over time upon exposure to blood, thereby
 increasing the duration of anticoagulant activity.  In this manner a high
 local heparin concentration at the device surface results in prolonged
 anti-thrombogenic protection while keeping the systemic concentrations low.
 The replacement of heparin systemically reduces the risk of further
 complications and additional testing.
     In a series of experiments, a catheter with MEDI-COAT(TM) heparin coating
 and a control catheter were placed in a rabbit's jugular vein for seven days.
 Upon removal the MEDI-COAT(TM) heparin layer prevented thrombus formation on
 the coated catheter, while considerable thrombus formation occurred on the
 control catheter surface.  In vitro studies have shown the heparin activity on
 catheter surfaces was extended from less than one hour for conventional
 treatments to well over two weeks with the MEDI-COAT(TM) treated surfaces.
     When used in combination with STS Biopolymers' unique BOND-COAT(TM) metal
 primer, the MEDI-COAT(TM) system can be employed on coronary stents to combat
 restenosis following coronary angioplasty.  This permanent surface treatment
 is specially designed for release of either single drug formulations or drug
 cocktails over a controlled period of time to the damaged blood vessels while
 maintaining the flexibility needed for stent placement.
 
     Recent news releases and other information are on the companies' Internet
 home page at http://www.stsbiopolymers.com.
 
     Image of the catheter comparison available upon request from STS
 Biopolymers.  MEDI-COAT and BOND-COAT are trademarks of STS Biopolymers, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X57139660
 
 

SOURCE STS Biopolymers, Inc.
    HENRIETTA, N.Y., April 25 /PRNewswire/ -- STS Biopolymers has developed
 heparin-containing polymer coatings (MEDI-COAT(TM)) for use on implants and
 indwelling devices, such as catheters and stents, to render them
 hemocompatible for sustained periods.  A research grant from the National
 Institutes of Health will allow STS Biopolymers to further develop and
 investigate "long-term" anti-thrombogenic surface coatings.
     When blood comes in contact with foreign surfaces there is an activation
 of the body's coagulation and inflammation systems, known as thrombosis.  The
 clinical means to prevent thrombosis is to administer systemic anticoagulants,
 such as heparin and warfarin.
     The STS Biopolymers' patented MEDI-COAT(TM) system consists of an inert,
 biocompatible polymer matrix used to entrap heparin complexes on the surface
 of medical devices.  The polymer coating acts as a reservoir for the heparin
 complex, releasing the agent slowly over time upon exposure to blood, thereby
 increasing the duration of anticoagulant activity.  In this manner a high
 local heparin concentration at the device surface results in prolonged
 anti-thrombogenic protection while keeping the systemic concentrations low.
 The replacement of heparin systemically reduces the risk of further
 complications and additional testing.
     In a series of experiments, a catheter with MEDI-COAT(TM) heparin coating
 and a control catheter were placed in a rabbit's jugular vein for seven days.
 Upon removal the MEDI-COAT(TM) heparin layer prevented thrombus formation on
 the coated catheter, while considerable thrombus formation occurred on the
 control catheter surface.  In vitro studies have shown the heparin activity on
 catheter surfaces was extended from less than one hour for conventional
 treatments to well over two weeks with the MEDI-COAT(TM) treated surfaces.
     When used in combination with STS Biopolymers' unique BOND-COAT(TM) metal
 primer, the MEDI-COAT(TM) system can be employed on coronary stents to combat
 restenosis following coronary angioplasty.  This permanent surface treatment
 is specially designed for release of either single drug formulations or drug
 cocktails over a controlled period of time to the damaged blood vessels while
 maintaining the flexibility needed for stent placement.
 
     Recent news releases and other information are on the companies' Internet
 home page at http://www.stsbiopolymers.com.
 
     Image of the catheter comparison available upon request from STS
 Biopolymers.  MEDI-COAT and BOND-COAT are trademarks of STS Biopolymers, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X57139660
 
 SOURCE  STS Biopolymers, Inc.